Is Lincoln Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Lincoln Pharmaceuticals Ltd is a good quality company .

Is Lincoln Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Lincoln Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Lincoln Pharmaceuticals share price return in the past 10 years?

Lincoln Pharmaceuticals Ltd share price has appreciated 30.3% annually (CAGR) over the past ten years.

Is Lincoln Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Lincoln Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Lincoln Pharmaceuticals?

The latest standalone P/E ratio of Lincoln Pharmaceuticals as of 23-Apr-2024 is 13.60.

What is the P/B ratio of Lincoln Pharmaceuticals?

The latest standalone P/B ratio of Lincoln Pharmaceuticals as of 23-Apr-2024 is 2.07.

What is the 52-week high and low of Lincoln Pharmaceuticals?

The 52-week high of Lincoln Pharmaceuticals is Rs. 754.25 and the 52-week low is Rs. 365.40.

Lincoln Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Lincoln Pharmaceuticals
Brand: Lincoln Pharmaceuticals

BSE: 531633 | NSE: LINCOLN | Pharmaceuticals & Drugs | Small Cap

Place order

Lincoln Pharma Share Price

₹594.40 1.65 0.28%
as on 23-Apr'24 14:47

10 Year X-Ray of Lincoln Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	10.3%	11.5%	13.2%	14%	12.8%	16.2%	14.7%	18.5%	17.2%	14.1%	-
Value Creation Index ⓘ	-0.3	-0.2	-0.1	0	-0.1	0.2	0.1	0.3	0.2	0.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	208	223	311	304	325	353	376	423	472	510	551
Sales YoY Gr.	-	7.1%	39.2%	-2.1%	6.8%	8.6%	6.5%	12.5%	11.6%	8.1%	-
Adj EPS ⓘ	7.2	8.2	12.2	13.6	15.1	21.8	21.6	30.7	33.9	32.3	43.6
YoY Gr.	-	13.9%	48.5%	11.8%	10.8%	44.5%	-0.9%	42.1%	10.5%	-4.7%	-
BVPS (₹) ⓘ	60.8	68.3	80.4	94.8	109.8	131.3	152.3	182.9	216.1	250.9	286.6
Adj Net Profit ⓘ	11.7	13.4	19.9	27.2	30.2	43.6	43.2	61.5	68	64.8	87
Cash Flow from Ops. ⓘ	9.2	8.8	28.9	17.8	21.3	51.1	70.7	69.4	76.2	39.2	-
Debt/CF from Ops. ⓘ	5.6	5.5	2.1	3	2.6	0.7	0.1	0	0	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.5%	9.5%	10.7%	8.1%
Adj EPS ⓘ	18.2%	16.5%	14.4%	-4.7%
BVPSⓘ	17.1%	18%	18.1%	16.1%
Share Price	30.3%	25.6%	31.8%	47.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	12.5	12.7	15.9	16.6	14.8	18.1	15.2	18.3	17	13.9	16.2
Op. Profit Mgn % ⓘ	9.2	10.5	10.6	14	14.2	17.1	15.9	20.6	20.3	17.5	17.8
Net Profit Mgn % ⓘ	5.6	6	6.4	9	9.3	12.4	11.5	14.6	14.4	12.7	15.9
Debt to Equity ⓘ	0.5	0.4	0.5	0.3	0.3	0.1	0	0	0	0	-
Working Cap Days ⓘ	272	248	168	198	221	223	227	227	226	231	137
Cash Conv. Cycle ⓘ	74	108	93	93	94	90	80	63	64	79	107

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 10.71%

Net Profit is growing at healthy rate in last 3 years 14.37%

Return on Equity has declined versus last 3 years average to 16.20%

Sales growth is not so good in last 4 quarters at 9.98%

Latest Financials - Lincoln Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	43.6	43.6
TTM Sales (₹ Cr.)	551	551
BVPS (₹.) ⓘ	286.6	286.6
Reserves (₹ Cr.) ⓘ	554	554
P/BV ⓘ	2.07	2.07
PE ⓘ	13.60	13.60

From the Market
52 Week Low / High (₹)	365.40 / 754.25
All Time Low / High (₹)	8.05 / 754.25
Market Cap (₹ Cr.)	1,187
Equity (₹ Cr.)	20
Face Value (₹)	10
Industry PE ⓘ	47.9

Management X-Ray of Lincoln Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Lincoln Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Lincoln Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	208	223	311	304	325	353	376	423	472	510
Operating Expenses ⓘ	190	200	278	262	279	293	317	336	377	421
Manufacturing Costs	18	23	29	32	39	45	48	69	78	96
Material Costs	134	131	189	158	152	157	163	155	170	179
Employee Cost	14	16	27	35	48	48	55	63	80	93
Other Costs ⓘ	25	30	34	37	41	42	50	49	50	53
Operating Profit ⓘ	19	23	33	42	46	60	59	87	95	89
Operating Profit Margin (%)	9.0%	10.3%	10.5%	13.9%	14.1%	17.1%	15.8%	20.6%	20.2%	17.5%
Other Income ⓘ	1	5	6	3	6	7	12	6	10	22
Interest ⓘ	5	6	6	5	4	4	2	2	1	2
Depreciation ⓘ	2	3	3	4	4	5	5	8	8	9
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	13	19	30	36	43	58	64	84	96	100
Tax ⓘ	1	4	8	8	10	12	14	21	27	28
Profit After Tax	11	15	22	27	33	47	50	62	69	73
PAT Margin (%)	5.5%	6.6%	7.0%	9.0%	10.1%	13.2%	13.2%	14.7%	14.7%	14.3%
Adjusted EPS (₹)	7.0	9.1	13.3	13.7	16.4	23.3	24.8	31.1	34.6	36.4
Dividend Payout Ratio (%)	9%	11%	8%	9%	9%	6%	6%	5%	4%	4%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	99	111	131	190	220	263	304	366	433	502
Share Capital ⓘ	16	16	16	20	20	20	20	20	20	20
Reserves ⓘ	83	95	115	170	200	243	284	346	413	482
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	51	48	59	51	55	32	4	0	2	2
Long Term Debt	3	0	9	7	6	2	1	0	0	0
Short Term Debt	48	48	50	44	49	30	4	0	2	2
Trade Payables	50	13	21	25	35	36	42	57	71	51
Others Liabilities ⓘ	20	23	31	33	32	47	61	78	79	81
Total Liabilities ⓘ	220	195	242	299	341	378	412	501	585	636
Fixed Assets
Gross Block	47	51	80	72	91	101	108	142	171	197
Accumulated Depreciation	15	18	17	4	8	12	17	31	39	47
Net Fixed Assetsⓘ	32	33	63	68	83	88	91	111	132	151
CWIP ⓘ	2	3	3	7	0	2	0	2	16	7
Investmentsⓘ	11	13	20	36	39	46	60	81	97	91
Inventories	21	19	25	32	36	29	38	47	73	70
Trade Receivables	87	82	75	79	96	113	91	112	115	135
Cash Equivalents	7	6	5	5	8	7	11	13	18	34
Others Assetsⓘ	59	39	51	72	78	91	121	136	134	148
Total Assets ⓘ	220	195	242	299	341	378	412	501	585	636

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	9	9	29	18	21	51	71	69	76	39
PBT ⓘ	13	19	30	36	43	58	64	84	96	100
Adjustment ⓘ	10	7	8	8	8	7	5	5	1	0
Changes in Working Capital ⓘ	-11	-14	-3	-17	-21	3	15	0	2	-31
Tax Paid ⓘ	-3	-3	-6	-9	-9	-17	-14	-19	-24	-30
Cash Flow From Investing Activity ⓘ	3	-5	-40	-26	-14	-22	-29	-64	-78	-37
Capex	-1	-4	-33	-17	-9	-11	-6	-9	-45	-14
Net Investments	3	0	0	-10	1	-6	-15	-44	-23	-4
Others ⓘ	1	-1	-7	1	-5	-5	-8	-11	-9	-19
Cash Flow From Financing Activityⓘ	-17	-5	11	8	-4	-30	-38	-6	-3	-5
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	8	-2	-1	-4	-3	-1	-1	0
Interest Paid ⓘ	-5	-4	-6	-5	-4	-4	-2	-1	-1	-1
Dividend Paid ⓘ	-1	-1	-2	-2	-3	-4	-7	0	-3	-3
Others ⓘ	-11	0	10	17	4	-18	-26	-4	2	0
Net Cash Flow ⓘ	-5	-1	0	0	4	-1	4	-1	-4	-2

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	12.16	14.04	17.94	17.09	16.01	19.35	17.48	18.56	17.35	15.59
ROCE (%)	11.89	16.46	19.83	18.63	18.28	21.68	21.81	25.21	24.29	21.82
Asset Turnover Ratio	0.98	1.09	1.45	1.14	1.02	1.01	0.99	0.96	0.91	0.87
PAT to CFO Conversion(x)	0.82	0.6	1.32	0.67	0.64	1.09	1.42	1.11	1.1	0.53
Working Capital Days
Receivable Days	138	136	91	91	98	105	96	85	83	86
Inventory Days	33	32	25	34	38	33	31	35	44	49
Payable Days	128	89	33	53	72	82	87	116	138	125

Lincoln Pharmaceuticals Ltd Stock News

Lincoln Pharmaceuticals Ltd FAQs

What is the share price of Lincoln Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Lincoln Pharma on 23-Apr-2024 14:47 is ₹594.4.

What is the market cap of Lincoln Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Apr-2024 14:47 the market cap of Lincoln Pharma stood at ₹1,187.3.

What is the P/E ratio of Lincoln Pharma?

The latest P/E ratio of Lincoln Pharma as of 23-Apr-2024 14:47 is 13.60.

What is the P/B ratio of Lincoln Pharma?

The latest P/B ratio of Lincoln Pharma as of 23-Apr-2024 14:47 is 2.07.

What is the 52-week high and low of Lincoln Pharma?

The 52-week high of Lincoln Pharma is ₹754.2 and the 52-week low is ₹365.4.

What is the TTM revenue of Lincoln Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lincoln Pharma is ₹550.5 ( Cr.) .

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals was established in 1979 to manufacture and market affordable therapeutic products. Since then, Lincoln Pharmaceuticals has come a long way.

Lincoln Pharmaceuticals is a public limited company with a large shareholder base including members of the medical fraternity. It has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters. There are three different buildings for tablets, capsules and injectables and also a separate building for quality control.

An ultramodern laboratory with state-of-the-art equipments ensures in-house quality assurance of each of the products. The products are designed for all therapeutic segments with a special emphasis on gynecological and orthopedic specialties.

Group of Companies